NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively conducts, or has completed, clinical research into the potential applications of TTFields for a broader spectrum of cancers. These investigational areas encompass brain metastases, gastric cancer, further studies in glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000, NovoCure Limited is headquartered in Saint Helier, Jersey.
